![Chris Storgard](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Chris Storgard
Technik-/Wissenschafts-/F&E-Leiter bei HERON THERAPEUTICS, INC.
Profil
Chris M.
Storgard is currently the Chief Medical Officer at Heron Therapeutics, Inc. He previously served as the Vice President-Clinical Research & Development at Ardea Biosciences, Inc. from 2013 to 2016 and as the Chief Medical Officer at Fate Therapeutics, Inc. from 2016 to 2018.
Prior to that, he was a Member & Assistant Professor at Mayo Medical School from 2001 to 2004.
Dr. Storgard holds a doctorate degree from the University of Saskatchewan.
Aktive Positionen von Chris Storgard
Unternehmen | Position | Beginn |
---|---|---|
HERON THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.11.2018 |
Ehemalige bekannte Positionen von Chris Storgard
Unternehmen | Position | Ende |
---|---|---|
FATE THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 05.11.2018 |
Ardea Biosciences, Inc.
![]() Ardea Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ardea Biosciences, Inc. is a biotechnology company which is focused on the development of small-molecule therapeutics for the treatment of serious diseases. The company was founded in January 1994 and is headquartered in Wilmington, DE. | Technik-/Wissenschafts-/F&E-Leiter | 02.01.2016 |
Mayo Medical School | Corporate Officer/Principal | 02.01.2004 |
Ausbildung von Chris Storgard
University of Saskatchewan | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
FATE THERAPEUTICS, INC. | Health Technology |
HERON THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Ardea Biosciences, Inc.
![]() Ardea Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ardea Biosciences, Inc. is a biotechnology company which is focused on the development of small-molecule therapeutics for the treatment of serious diseases. The company was founded in January 1994 and is headquartered in Wilmington, DE. | Health Technology |